Bisorcic

Bisorcic

Clinical data
Other names	N2,N5-Diacetyl-L-ornithine; N2,N5-Diacetylornithine; Nα,Nδ-Diacetylornithine
Routes of administration	Oral [1]
Drug class	Hepatoprotective agent; Psychostimulant [2] [1]
Identifiers
IUPAC name (2S)-2,5-diacetamidopentanoic acid
CAS Number	39825-23-5
PubChem CID	65977
ChemSpider	59375
UNII	3V77J79MIF
ChEBI	CHEBI:133217
ChEMBL	ChEMBL3989425
CompTox Dashboard (EPA)	DTXSID50960387
ECHA InfoCard	100.049.659
Chemical and physical data
Formula	C9H16N2O4
Molar mass	216.237 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)NCCC[C@@H](C(=O)O)NC(=O)C
InChI InChI=1S/C9H16N2O4/c1-6(12)10-5-3-4-8(9(14)15)11-7(2)13/h8H,3-5H2,1-2H3,(H,10,12)(H,11,13)(H,14,15)/t8-/m0/s1 Key:XUYANFPPYJSBPU-QMMMGPOBSA-N

Bisorcic (INN Tooltip International Nonproprietary Name), also known as N²,N⁵-diacetyl-L-ornithine, is a drug described as a hepatoprotective agent and "psychostimulant" which has been used in France in the treatment of asthenia. ^{[2] [3] [4] [5] [1]} It is the N²,N⁵-diacetylated derivative of the amino acid L-ornithine. ^[6]

Bisorcic was first described in the literature in 1973 in a German patent. ^[2] The INN Tooltip International Nonproprietary Name was designated around 1975. ^[7] The drug was marketed in France by Astyl-Gallier in 1987. ^[1] It was provided in the form of 200 mg oral capsules and four capsules were taken daily. ^[1]

L-Ornithine, as the combination drug L-ornithine L-aspartate (LOLA), has been used in the treatment of hepatic encephalopathy and cirrhosis and is likewise described as hepatoprotective. ^{[8] [9]} It is thought to work by participating in the urea cycle and lowering ammonia levels. ^{[8] [9]}

References

1. Schlesser JL (1990). Drugs Available Abroad: A Guide to Therapeutic Drugs Available and Approved for Use Outside the U. S. Gale Research; Derwent Publications Ltd. p. 24. ISBN   978-0-8103-7177-4 . Retrieved 28 September 2024. 109 BISORCIC. Countries Where Available and Release Dates: France (1987). Brand Names and Manufacturers: Astyl-Gallier (France). Drug Action: Psychostimulant. Indications/Usage: Asthenia. How Supplied: 200 mg capsules. Dosage: 4 capsules daily. Not recommended in children. Contraindications: Epilepsy.
2. Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 906. ISBN   978-1-4757-2085-3 . Retrieved 28 September 2024. N^α,N^δ-Di-Ac: [39825-23-5]. N²,N⁵-Diacetylornithine, 9Cl. Bisorcic, INN. 69H16N2O4. M 216,236. Hepatoprotective agent, psychostimulant. [...] Ger. Pat., 2 219 874, (1973); CA, 78, 98010t (Bisorcic).
3. Buckingham J (2020). Dictionary of Natural Products. CRC Press. p. 356. ISBN   978-1-000-15302-6 . Retrieved 28 September 2024.
4. Blunt JW, Munro MH (2007). Dictionary of Marine Natural Products with CD-ROM. CRC Press. p. 522. ISBN   978-0-8493-8217-8 . Retrieved 28 September 2024.
5. Negwer M (1994). Organic-chemical Drugs and Their Synonyms: (an International Survey). Akademie Verlag. p. 359. ISBN   978-3-05-500156-7 . Retrieved 28 September 2024. 6220. 39825-23-5 CI CI -NH2 N C10H10CI2N2O2 51 230-28-5. N2,N5-Diacetyl-L-ornithine. R see also no. 3704. S Bisorcic**. U Psychostimulant.
6. "Bisorcic". PubChem. U.S. National Library of Medicine. Retrieved 28 September 2024.
7. "Proposed International Nonproprietary Names (Prop. INN): List 34. International Nonproprietary Names for Pharmaceutical Substances" (PDF). Supplement to WHO Chronicle. 29 (9). 1975. Retrieved 28 September 2024.
8. Kircheis G, Lüth S (February 2019). "Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy". Drugs. 79 (Suppl 1): 23–29. doi:10.1007/s40265-018-1023-2. PMC   6416235 . PMID   30706424.
9. Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY (May 2018). "L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis". The Cochrane Database of Systematic Reviews. 5 (5) CD012410. doi:10.1002/14651858.CD012410.pub2. PMC   6494563 . PMID   29762873.